Humana Extends TailorCare Tie-Up to Enhance MA Member Health

24.09.25 20:15 Uhr

Werte in diesem Artikel
Aktien

218,40 EUR 0,90 EUR 0,41%

Indizes

6.638,0 PKT -19,0 PKT -0,28%

Humana Inc. HUM recently solidified its partnership with TailorCare, a leading value-based specialty care provider for musculoskeletal (MSK) health, to serve Medicare Advantage (MA) members in Dallas and Denver. Starting in November 2025 in Dallas and in January 2026 in Denver, Humana MA members can avail TailorCare’s personalized, evidence-based MSK navigation and care coordination services. It already serves HUM members across Atlanta. TailorCare’s approach begins early in the care journey to prevent pain from progressing to invasive or avoidable treatments. Each Humana MA member referred to the program undergoes a structured evaluation with a licensed physical therapist. This assessment leads to a tailored care plan, which may encompass conservative therapy, in-person physical therapy, specialist referrals within the network, and self-care guidance at home.As a result of the expanded tie-up, Humana members will also benefit from one of the most advanced home-based physical therapy programs in the country, offering more than 225 evidence-based clinical pathways with personalized exercise routines, certified health coaching for lifestyle support and sensor-free motion tracking technology for progress monitoring. The recent move also seems to be a time-opportune one since musculoskeletal disorders, including arthritis, osteoporosis and joint issues, affect a significant portion of the American population and lead to escalating healthcare costs.Benefits of the Recent Move to HumanaHumana aims to improve health outcomes for its MA members suffering from joint, back and muscle conditions as a result of the expanded partnership, while reducing unnecessary procedures and high costs.The beneficial nature of TailorCare services is likely to retain existing MA customers and attract new ones to opt for Humana’s healthcare plans. Increased plan adoption is expected to expand HUM’s MA membership base and bring higher premium revenues to the health insurer. Total MA membership came in at 5.8 million as of June 30, 2025. Overall premiums advanced 8.6% year over year in the first half of 2025.HUM’s Share Price Performance & Zacks RankShares of Humana have gained 8.3% in the past three months compared with the industry’s 3.5% growth. HUM currently carries a Zacks Rank #3 (Hold).Image Source: Zacks Investment ResearchStocks to ConsiderSome better-ranked stocks in the Medical space are ANI Pharmaceuticals, Inc. ANIP, The Ensign Group, Inc. ENSG and Novartis AG NVS. While ANI Pharmaceuticals sports a Zacks Rank #1 (Strong Buy), Ensign Group and Novartis carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.ANI Pharmaceuticals’ earnings surpassed estimates in each of the last four quarters, the average surprise being 22.66%. The Zacks Consensus Estimate for ANIP’s 2025 earnings indicates a rise of 39.8% while the same for revenues implies an improvement of 36.9% from the respective year-earlier actuals. The consensus mark for ANIP’s earnings has moved 11% north in the past 60 days. The bottom line of Ensign Group outpaced estimates in each of the trailing four quarters, the average surprise being 1.85%. The Zacks Consensus Estimate for ENSG’s 2025 earnings indicates a rise of 16.2% while the same for revenues implies an improvement of 17.2% from the respective year-earlier actuals. The consensus mark for ENSG’s earnings has moved 1.3% north in the past 60 days.Novartis’ earnings surpassed estimates in each of the last four quarters, the average surprise being 6.20%. The Zacks Consensus Estimate for NVS’ 2025 earnings indicates a rise of 15.2% while the consensus mark for revenues implies an improvement of 10.5% from the respective year-earlier actuals. The consensus mark for NVS’ earnings has moved 0.4% north in the past 60 days.Shares of ANI Pharmaceuticals, Ensign Group and Novartis have gained 44.2%, 11.2% and 4.1%, respectively, in the past three months.   Quantum Computing Stocks Set To SoarArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.Access the Report Free Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report The Ensign Group, Inc. (ENSG): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Humana und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!

Ausgewählte Hebelprodukte auf Humana

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Humana

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Humana Inc.

Wer­bung

Analysen zu Humana Inc.

DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
09.11.2017Humana Sector PerformRBC Capital Markets
20.10.2017Humana OutperformBMO Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
DatumRatingAnalyst
12.08.2019Humana OverweightCantor Fitzgerald
13.09.2018Humana OverweightBarclays Capital
20.10.2017Humana OutperformBMO Capital Markets
24.01.2017Humana HoldStifel, Nicolaus & Co., Inc.
05.05.2016Humana BuyStifel, Nicolaus & Co., Inc.
DatumRatingAnalyst
09.11.2017Humana Sector PerformRBC Capital Markets
05.04.2017Humana HoldDeutsche Bank AG
07.12.2016Humana HoldCantor Fitzgerald
13.10.2016Humana Sector PerformRBC Capital Markets
22.07.2016Humana Mkt PerformFBR Capital
DatumRatingAnalyst
14.03.2008Humana neues KurszielLehman Brothers Inc.
03.02.2006Update Humana Inc.: UnderperformCredit Suisse First Boston
26.01.2006Update Humana Inc.: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Humana Inc. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen